Zydus US031
Welcome,         Profile    Billing    Logout  
 1 Trial 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Haroldsen, Anne
EPICS-III, NCT05133336: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25
FMT IND, NCT05516472: Fecal Microbiota Transplantation in Kidney Stone Patients

Recruiting
1
36
US
Microbial Transplant Therapy, fecal transplant, Placebo
Joshua Stern, University of Minnesota, Albert Einstein College of Medicine, Litholink Corporation
Kidney Stones
12/26
03/27
PROGRESS, NCT05612750: Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The Study

Recruiting
N/A
1200
US
Education
Stanford University, Patient-Centered Outcomes Research Institute
Pain, Chronic
05/28
05/28
MAbPACs, NCT05013723: Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

Not yet recruiting
N/A
260
US
Surveys
Intermountain Health Care, Inc., Regeneron Pharmaceuticals
Post-acute COVID-19 (PACS), or "Long COVID" Syndrome
02/22
04/22
Hossain, Zakir
EPICS-III, NCT05133336: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis

Active, not recruiting
2/3
186
NA
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
05/25
05/25
Unsworth, Anika
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis

Recruiting
3
150
NA
Saroglitazar Magnesium 1 mg
Zydus Therapeutics Inc.
Primary Biliary Cholangitis
04/27
07/27

Download Options